Skip to main content
SpringerLink
Log in

Alglucosidase-alfa not cost effective for Pompe disease

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 euros

Reference

  • Kanters TA, et al. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Orphanet Journal of Rare Diseases : 13 Dec 2017. Available from: URL: https://doi.org/10.1186/s13023-017-0731-0

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alglucosidase-alfa not cost effective for Pompe disease. PharmacoEcon Outcomes News 794, 6 (2018). https://doi.org/10.1007/s40274-018-4604-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4604-0

Search

Navigation